Demand is rising across Nigeria for Lenacapavir, a newly introduced twice-yearly HIV prevention injection, even before its full nationwide rollout.
Reports said that many Nigerians – particularly those familiar with pre-exposure prophylaxis (PrEP) – are already approaching health centres and NGOs seeking access to the drug, driven by growing awareness and anticipation.
Lenacapavir, developed by Gilead Sciences and endorsed by the World Health Organization in 2025, offers a long-acting alternative to daily HIV prevention pills.
The Federal government, through the National HIV, Viral Hepatitis and STDs Control Programme, has begun deploying the injection in selected pilot states, with about 11,520 doses already delivered out of an expected 52,000.
Pilot states include Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, Gombe, Kano, Kwara and Lagos, alongside the Federal Capital Territory, with official unveiling scheduled for March 24.
Health workers are currently undergoing training, while the injection – offered free of charge – will be administered at designated public health facilities rather than pharmacies.
Reports from states such as Anambra, Benue, and Osun indicate strong demand, particularly among high-risk groups, including discordant couples and even health workers seeking preventive protection.
However, experts have raised concerns over misconceptions, warning that Lenacapavir is not a cure for HIV but a preventive option for uninfected individuals. Advocacy groups also called for wider awareness to ensure proper use.
While early data suggest minimal side effects, the Pharmaceutical Society of Nigeria (PSN) has urged strict regulatory oversight, noting that agencies such as National Agency for Food and Drug Administration and Control (NAFDAC) must complete safety and efficacy assessments before broader deployment.
With Nigeria still recording about two million people living with HIV, stakeholders say the successful rollout of Lenacapavir could significantly reduce new infections if properly implemented and widely understood.
